dna-methylation
(3)
ARNA Genomics US Inc.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.
Generation Lab
Generation Lab is a San Francisco longevity biotech building SystemAge, a diagnostic that measures how fast your body is actually aging rather than predicting a number. Using DNA methylation analysis of hundreds of biomarkers, it reports biological ages across roughly 19 organ systems from a blood sample, then hands clinicians an actionable plan to track whether interventions are moving the needle. Founded in 2023 by CEO Alina Rui Su, UC Berkeley aging researcher Dr. Irina Conboy, and operator Michael Suswal, the company raised an $11M seed in October 2025 led by Accel and works with 275+ clinics across roughly 18 countries.
ClearNote Health
ClearNote Health is a San Diego molecular diagnostics company building non-invasive, blood-based tests that detect high-mortality cancers early, when treatment works best. Spun out of Stephen Quake's Stanford lab in 2016 (originally as Bluestar Genomics), it pairs a proprietary 5-hydroxymethylcytosine (5hmC) epigenomic platform with cell-free DNA analysis and machine learning. Its flagship Avantect Pancreatic Cancer Test targets high-risk patients - including adults 50+ newly diagnosed with type 2 diabetes - and the company is extending the approach to ovarian and multi-cancer detection.